The Clinical Significance of the Emergence of Drug-Resistant Organisms during the Therapy of Chronic Pulmonary Tuberculosis with Hydrazides of Isonicotinic Acid
- 25 June 1953
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 248 (26), 1081-1087
- https://doi.org/10.1056/nejm195306252482601
Abstract
SOON after the discovery of the potent antituberculosis effect of the isoniazid drugs in laboratory animals in 1951, a number of reports appeared describing their value in patients with pulmonary tuberculosis.1 , 2 Emergence of drug-resistant tubercle bacilli, or indication of such a phenomenon, was not reported in those studies although observations soon became available demonstrating that increased bacterial resistance to the drugs may appear rapidly during therapy with either isoniazid or iproniazid alone.3 4 5 6 7 8 9 The relative frequency and consistency of this phenomenon during isoniazid therapy have recently been confirmed by large and carefully controlled studies.10 11 12 13 However, uncertainty still exists regarding the clinical . . .Keywords
This publication has 7 references indexed in Scilit:
- Clinical Experiences with Isonicotinic Acid Hydrazide in TuberculosisDiseases of the Chest, 1953
- ISONIAZID IN PULMONARY TUBERCULOSISThe Lancet, 1952
- Treatment of Pulmonary Tuberculosis with Isoniazid: A Medical Research Council InvestigationBMJ, 1952
- Development of drug resistance to isoniazid in cases of pulmonary tuberculosisTubercle, 1952
- DENMARKPublished by American Medical Association (AMA) ,1952
- RELATION BETWEEN IN-VITRO AND IN-VIVO RESISTANCE TO ISONIAZIDThe Lancet, 1952
- Tuberculosis Chemotherapy with Hydrazine Derivatives of Isonicotinic AcidDiseases of the Chest, 1952